Research has demonstrated that deucravacitinib is significantly more efficacious than placebo for achieving minimal disease activity in patients with active PsA after 16 weeks of treatment.

Research has demonstrated that deucravacitinib is significantly more efficacious than placebo for achieving minimal disease activity in patients with active PsA after 16 weeks of treatment.
In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.
This EULAR 2022 session emphasized the importance of recognizing the axial manifestations of psoriatic arthritis and treating these symptoms accordingly.
A study from Haibel et al. in patients with chronic knee arthritis found intra-articular morphine did not lead to a significant, short-term reduction in pain compared with placebo and proved inferior to treatment with intra-articular triamcinolone.
Ian D. Cooley, MD, & Eli M. Miloslavsky, MD |
Teaching junior learners, such as medical students and residents, is increasingly important in rheumatology. Given the anticipated shortage of rheumatologists, attracting more trainees to our field and enhancing knowledge of the rheumatic diseases among physicians in other fields are critical to meeting the needs of our patients.1,2 In addition, clinical reasoning is a vital skill…
Dana DiRenzo, MD, MHS |
The prescription is a powerful tool for a physician. As rheumatologists, we prescribe many things—drugs, physical therapy, durable medical equipment—but what about stress reduction? We are very specific about times of day to take medications and in what manner. Patients ask: With or without food? With other medications? Before or after other prescribed medications? If…
Fazila Aseem, MD, MPH, Alexander D. Jeffs, MD, Enid Y. Sun, MD, MPH, Randaline R. Barnett, MD, Courtney Blodgett, AG-ACNP, Winnie Lau, MD, Casey Olm-Shipman, MD, MS, Matthew F. Sharrock, MD, Rhonda Cadena, MD, Yueh. Z. Lee, MD, PhD, Alfredo C. Rivadeneira, MD, & Clio A. Rubinos, MD, MS |
Scleromyxedema is a primary cutaneous mucinosis characterized by a diffuse and generalized papular skin eruption of mucinous deposits throughout the upper dermis. In addition to dermatologic manifestations, scleromyxedema may involve the cardiopulmonary, gastrointestinal, renal and nervous systems. Dermato-neuro syndrome (DNS) is a rare, severe neurologic complication of scleromyxedema.1,2 The pathogenesis of DNS is unknown, but…
Ryan Guerrettaz, MD, Angelo Ciliberti, MD, Rochella Ostrowski, MD, Elise Wolff, DO, Nadia Qureshi, MD, & Ramzan Shahid, MD |
Acute febrile neutrophilic dermatosis, or Sweet syndrome, is an inflammatory disease that classically presents with fever, leukocytosis and tender, erythematous plaques characterized by neutrophilic infiltrates on biopsy. Sweet syndrome has been reported in association with several autoimmune diseases, including inflammatory bowel disease, systemic lupus erythematous, rheumatoid arthritis and sarcoidosis.1 Here, we discuss a case of…
As the result of years of coalition work with partners at the AMA, the ACR recently celebrated a major advocacy win when the FTC announced an investigation of PBM business practices. Join or renew your AMA membership before Sept. 1 so the ACR can keep delegate seats to drive action within the AMA.
Background & Objectives Worldwide, osteoarthritis (OA) is a highly prevalent, chronic joint disease that causes pain, disability and loss of function. Global trends demonstrated an increase of more than 100% in years lived with disability due to OA from 1990 to 2019. However, no nonsurgical intervention exists to prevent, halt or even delay OA progression….